Advisory Alpha’s Immunogen Inc IMGN Stock Holding History

Advisory Alpha’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-165	Closed	-$706	–	661
2020 Q1	$706	Hold	165	–	–	﹤0.01%	654
2019 Q4	$733	Buy	+165	New	+$560	﹤0.01%	703

Other funds holding IMGN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Advisory Alpha's IMGN Position: Q2 2020 in Review

Advisory Alpha sold out of Immunogen Inc (IMGN) in Q2 2020, closing a stake of 165 shares — an estimated $706 sold.

Advisory Alpha first reported a position in IMGN in Q4 2019 and held it in 2 quarters. The position peaked at $733 in Q4 2019. 189 funds tracked by Wall St. Rank hold IMGN as of Q2 2020.

Advisory Alpha reported no remaining Immunogen Inc position as of Q2 2020 after selling out during the quarter.
Advisory Alpha sold 165 Immunogen Inc shares in Q2 2020, an estimated $706.
Advisory Alpha first reported a position in Immunogen Inc in Q4 2019 and held it in 2 quarters.
Advisory Alpha's Immunogen Inc position peaked at $733 in Q4 2019.
189 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2020.

Based on Advisory Alpha's 13F filing for Q2 2020, filed 14 Aug 2020.